News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Rapid Readout: Expert Perspectives on Multiple Sclerosis - Data from the 8th Joint ACTRIMS-ECTRIMS Meeting 2020

EP. 1: Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 2: OLKIOS: Looking at Ofatumumab’s Continued Efficacy

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 3: OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 4: Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 5: Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 6: Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 7: OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 8: OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 9: Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 10: Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 11: Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 12: Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 13: CLARITY Extension Trial: Disability Improvement With Cladribine

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 14: COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

EP. 15: Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Del-Desiran Fails to Meet Primary Endpoint in Phase 3 HARBOR Trial of Myotonic Dystrophy 1

Investigational Zorevunersen Linked to Adaptive Gains in Dravet Syndrome

Excessive Daytime Sleepiness Associated With Cognitive Deficits and Abnormal Brain Network Topology in Obstructive Sleep Apnea

NeuroVoices: Jacqueline Becker, PhD, on Brain Fog, Alzheimer Risk, and Treatment Advances in Long COVID

Building a Practical Diagnostic Workup for Suspected Epilepsy